H.C. Wainwright has revised its price target for Ekso Bionics (EKSO, Financial), cutting it to $4 from the previous $9. Despite this adjustment, the firm maintains a Buy rating for the stock. This change comes in the wake of Ekso Bionics' first-quarter report, which revealed a decline in enterprise revenue. The shortfall is attributed to reductions in customer budgets, according to the analyst's note to investors.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Ekso Bionics Holdings Inc (EKSO, Financial) is $5.00 with a high estimate of $9.00 and a low estimate of $1.00. The average target implies an upside of 949.54% from the current price of $0.48. More detailed estimate data can be found on the Ekso Bionics Holdings Inc (EKSO) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Ekso Bionics Holdings Inc's (EKSO, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Ekso Bionics Holdings Inc (EKSO, Financial) in one year is $1.27, suggesting a upside of 166.58% from the current price of $0.4764. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Ekso Bionics Holdings Inc (EKSO) Summary page.
EKSO Key Business Developments
Release Date: May 05, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Ekso Bionics Holdings Inc (EKSO, Financial) reported a gross margin increase to 54% in Q1 2025, up from 52% in the same period of 2024, driven by cost savings in supply chain and reduced service costs.
- The company has successfully engaged Pre-Healthcare to enhance market access services, which has been instrumental in the commercialization of over 300 medical devices.
- Ekso Bionics Holdings Inc (EKSO) has developed a pipeline of more than 35 Medicare beneficiaries as potential candidates for their exo Indigo Personal device, marking a 37% increase from the previous quarter.
- The company has strengthened its distribution network by partnering with National Seating and Mobility and Bionic P&O, which is expected to broaden access to their exoskeleton devices across the United States.
- Ekso Bionics Holdings Inc (EKSO) reported an increase in cash and restricted cash to $8.1 million as of March 31, 2025, up from $6.5 million at the end of 2024, indicating improved financial stability.
Negative Points
- Revenue for Q1 2025 decreased to $3.4 million from $3.8 million in the same period of 2024, primarily due to capital budget impacts on inpatient rehabilitation facilities.
- The company reported a net loss of $2.9 million for Q1 2025, although this was an improvement from a $3.4 million loss in Q1 2024.
- There is uncertainty regarding the capital budgets of inpatient rehabilitation facilities, which could impact future sales of Ekso Bionics Holdings Inc (EKSO)'s enterprise health products.
- The company faces challenges in ensuring successful Medicare claim submissions due to the lack of a definitive set of criteria published by CMS or DME MACs.
- Ekso Bionics Holdings Inc (EKSO) anticipates potential longer-term impacts on capital budgets due to economic uncertainties, which could affect their enterprise health business.
